Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Abstract Background The Khorana score is a validated tool to identify cancer patients at
higher risk of venous thromboembolism (VTE). Objective We compared its predictive …

Essentials• Venous thromboembolism (VTE) prevention strategies require effective risk
assessment models.• We sought to validate the Khorana Risk Score (KRS) in patients with …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …

Patients with cancer are heterogeneous concerning the risk for VTE. Some solid
malignancies including pancreatic, lung, colon-rectum, ovarian, and brain cancer are …

Background Current risk assessment models (RAMs) for prediction of venous
thromboembolism (VTE) risk in the outpatient cancer population have shown poor predictive …

Abstract Background Risk assessment models (RAMs) are relevant approaches to identify
cancer outpatients at high risk of venous thromboembolism (VTE). Among the proposed …